Treatment of Latent Tuberculosis Infection With Isoniazid
Tuberculosis
About this trial
This is an interventional diagnostic trial for Tuberculosis focused on measuring Latent tuberculosis, biomarkers, isoniazid, ELISPOT, PPD positive individuals
Eligibility Criteria
Inclusion criteria: Informed consent Age 10-45 Either sex Resident in study area Documented TST+ve (>10mm, Mantoux method, 2TU, PPD Statens Serum Institute) Normal chest radiograph HIV negative test Exclusion criteria: Active tuberculosis Previous diagnosis of tuberculosis Treatment for active or latent tuberculosis Contact with TB patients harboring MDR or INH resistant isolates of Mtb Diseases or therapies associated with immunosuppression Diabetes mellitus Abnormal liver enzyme levels. HB below 8gr/dl Pregnancy (ascertained by urinary β-HCG) Allergy or intolerance to isoniazid Peripheral neuropathy Ingestion of drugs interacting with isoniazid
Sites / Locations
- Instituto Nacional de Salud Pública
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Active Comparator
Experimental
Active Comparator
A
B
C
D
Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment.
B. Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.
C. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment
D. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.